At the news
? MIXEDIMPACT 6/10 8-K filed Mar 12, 2026 at 08:11 ET
Theriva Biologics reported financial results for 2025 and provided corporate updates, including licensing SYN-020 to Rasayana Therapeutics for up to $38 million in potential milestones, advancing VCN-01 toward pivotal trials in pancreatic cancer and retinoblastoma, and maintaining a cash runway into Q1 2027. The company incurred a net loss of $23.7 million in 2025, driven by a $9 million contingent consideration adjustment.
- Licensed SYN-020 to Rasayana Therapeutics for up to $38 million in potential milestones plus royalties
- Received $300,000 upfront payment from Rasayana with potential for $16M in development milestones and $22M in sales milestones
- Cash and cash equivalents were $13.1 million as of December 31, 2025, with $15.2 million as of February 26, 2026
- Net loss of $23.7 million for 2025, compared to $25.7 million in 2024
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access